ClinicalTrials.gg
CompletedNCT06106022Updated Dec 19, 2024Results posted

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

A Phase 1 interventional study of Vonoprazan in Gastroesophageal Reflux Disease, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Enrollment
15th of 16
22 · median 118
Started
2023
the only one that year
Phase 1
5 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
4 of 16
Phathom Pharmaceuticals, Inc.

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 15th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 1, and was the 9th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to \< 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • Gastrology
  • Vonoprazan
  • Gastroesophageal Reflux Disease
  • Children
  • GERD
  • Pharmacokinetics
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has a body weight within the 5th through 95th percentile by age, inclusive, as determined by the National Center for Health Statistics.
  2. The participant must have a diagnosis of GERD prior to randomization and medical history of signs or symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the electronic case report form (eCRF).
  3. The participant has at least one moderate GERD symptom based on the GERD Symptom Assessment Investigator scale performed at screening.
  4. The participant must be able to swallow study drug tablet with water.
  5. Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and able to complete the process and participants are able to comply with study procedures and visit schedule.
  6. Female participants who have experienced menarche must have a negative pregnancy test and will be counseled on pregnancy avoidance.

Exclusion criteria

Exclusion Criteria:

  1. The participant has used prescription or non-prescription proton pump inhibitors (PPIs) or histamine-2 receptor antagonist (H2RAs) within 7 days prior to randomization or requires use during the Treatment Period.
  2. The participant has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period.
  3. The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study.
  4. The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study.
  5. The participant has received any compound (including vonoprazan) within 30 days prior to the start of the Screening Period.
  6. The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or participant may have consented under duress.
  7. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period.
  8. The participant has undergone prior gastrointestinal surgeries.
  9. The participant has any abnormal laboratory test values that are considered in the opinion of the investigator during the Screening Period.
  10. The participant has a history of or allergies to vonoprazan (including the formulation : D-mannitol, microcrystalline cellulose, hydroxypropylcellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium dioxide, or red or yellow ferric oxide).
  11. The participant has used any prescription or over-the-counter medications (including herbal or nutritional supplements), other than those already excluded in criteria 1 to 5 above, within 14 days before the first dose of study drug or throughout the study. That is, unless the medication(s) is permitted by the sponsor following a review of available data which confirms concomitant administration of the medication is unlikely to affect either the safety of the participant or the pharmacokinetics of vonoprazan.
  12. The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study.
  13. The participant has positive results at screening for , virus, or virus (HCV).
  14. The participant has severe renal impairment (estimated \< 30 mL/min).
  15. The participant has moderate to severe hepatic impairment ( Class B and Child-Pugh Class C).
  16. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:

    1. Creatinine levels: >0.8 mg/dL (>70 μmol/L).
    2. (ALT) or aspartate aminotransferase (AST) >2 × the (ULN) or total >2 × ULN (except participants with Gilbert Syndrome).
  17. In the opinion of the investigator, the participant is not suitable for entry into the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Vonoprazan 10mg

    Participants will receive vonoprazan 10mg QD for 14 days.

    Drug: Vonoprazan

  • Experimental
    Vonoprazan 20mg

    Participants will receive vonoprazan 20mg QD for 14 days.

    Drug: Vonoprazan

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan

    Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

    Time frame: Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose

  2. Area Under the Plasma Concentration-time Curve During the Dosing Interval τ at Steady State (AUCτ,ss) of Vonoprazan

    Plasma PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

    Time frame: Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose

  3. Apparent Oral Clearance (CL/F) at Steady State of Vonoprazan

    Oral PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

    Time frame: Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose

  4. Apparent Central Volume of Distribution (Vz/F) at Steady State of Vonoprazan

    Plasma PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

    Time frame: Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose

07

Results

Posted Dec 19, 2024

Participant flow

A total of 22 participants were enrolled at 6 study sites in the United States between November 2023 and April 2024.

Participant flow — Overall Study
MilestoneVonoprazan 10 mgVonoprazan 20 mg
Started1111
Completed109
Not completed12
Withdrew: Lost to follow-up10
Withdrew: Voluntary withdrawal02

Outcome measures

PrimaryMaximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan

Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

Time frame:
Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose
Reported as:
Mean · ng/mL
Maximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan
ng/mLVonoprazan 10 mgVonoprazan 20 mg
Maximum Drug Concentration at Steady-state (Cmax,ss) of Vonoprazan16.2 (9.31 to 27.1)42.1 (10.1 to 72.7)
PrimaryArea Under the Plasma Concentration-time Curve During the Dosing Interval τ at Steady State (AUCτ,ss) of Vonoprazan

Plasma PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

Time frame:
Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve During the Dosing Interval τ at Steady State (AUCτ,ss) of Vonoprazan
h*ng/mLVonoprazan 10 mgVonoprazan 20 mg
Area Under the Plasma Concentration-time Curve During the Dosing Interval τ at Steady State (AUCτ,ss) of Vonoprazan88.3 (51.7 to 121)251 (72.1 to 549)
PrimaryApparent Oral Clearance (CL/F) at Steady State of Vonoprazan

Oral PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

Time frame:
Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose
Reported as:
Mean · L/h
Apparent Oral Clearance (CL/F) at Steady State of Vonoprazan
L/hVonoprazan 10 mgVonoprazan 20 mg
Apparent Oral Clearance (CL/F) at Steady State of Vonoprazan125 (82.9 to 193)118 (36.4 to 278)
PrimaryApparent Central Volume of Distribution (Vz/F) at Steady State of Vonoprazan

Plasma PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time. Data presented based on collections on both Day 7 and Day 14.

Time frame:
Day 7: pre-dose, 0.5 to 1.5 hour and 2.5 to 3.5 hours post dose; Day 14: pre-dose, 1 to 2 hours and 3 to 4 hours post dose
Reported as:
Mean · liters
Apparent Central Volume of Distribution (Vz/F) at Steady State of Vonoprazan
litersVonoprazan 10 mgVonoprazan 20 mg
Apparent Central Volume of Distribution (Vz/F) at Steady State of Vonoprazan491 (227 to 828)444 (164 to 1310)

Adverse events

Collected over Up to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 10 mg0/11 (0%)0/11 (0%)1/11 (9.1%)
Vonoprazan 20 mg0/11 (0%)0/11 (0%)0/11 (0%)
Most frequent other events
Most frequent other events
EventVonoprazan 10 mgVonoprazan 20 mg
Tympanic membrane perforationEar and labyrinth disorders1/110/11
VomitingGastrointestinal disorders1/110/11
Otitis mediaInfections and infestations1/110/11
Electrocardiogram QT prolongedInvestigations1/110/11

Baseline characteristics

Safety Set: includes all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vonoprazan 10 mgVonoprazan 20 mgTotal
Mean9.1 ± 1.928.6 ± 1.698.9 ± 1.78
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 10 mgVonoprazan 20 mgTotal
Female7512
Male4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vonoprazan 10 mgVonoprazan 20 mgTotal
Hispanic or Latino6915
Not Hispanic or Latino527
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vonoprazan 10 mgVonoprazan 20 mgTotal
White101020
Black or African American112
08

Study locations

13 sites
  • Strada Patient Care Center
    Mobile, Alabama 36604, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Med Research Associates, Inc
    Hollywood, Florida 33024, United States
  • Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • International Center for Research
    Tampa, Florida 33614, United States
  • Children's Center for Digestive Health Care, LLC
    Atlanta, Georgia 30342, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • Tandem Clinical Research GI, LLC
    Marrero, Louisiana 70072, United States
  • Advantage Clinical Trials
    Bronx, New York 10467, United States
  • PriMED Clinical Research
    Dayton, Ohio 45429, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • Maspons Pediatric Gastro
    El Paso, Texas 79902, United States
  • Stryde Research - NxT Step Pediatrics
    Frisco, Texas 75033, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Apr 2024, 5 months.

Results were first posted in Dec 2024, 8 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 5 months is above that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Nov 1, 2023
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 29, 2024
Results first posted
Dec 19, 2024
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06106022
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Nov 1, 2023
Primary completion
Apr 16, 2024
Completion
Apr 29, 2024
Results posted
Dec 19, 2024
Last update
Dec 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion